CA2331120A1 - Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie - Google Patents

Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie Download PDF

Info

Publication number
CA2331120A1
CA2331120A1 CA002331120A CA2331120A CA2331120A1 CA 2331120 A1 CA2331120 A1 CA 2331120A1 CA 002331120 A CA002331120 A CA 002331120A CA 2331120 A CA2331120 A CA 2331120A CA 2331120 A1 CA2331120 A1 CA 2331120A1
Authority
CA
Canada
Prior art keywords
carbon atoms
alkyl
hydrogen
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002331120A
Other languages
English (en)
Inventor
Iwan Gunawan
Zenan Li
Michael Sotirios Malamas
Arlene Joan Dietrich
Jay Edward Wrobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2331120A1 publication Critical patent/CA2331120A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés de la formule structurelle (I) dans laquelle A représente O, S, ou N, B représente -(CH¿2?)¿m?-, -CH(OH)- ou carbonyle, R?1¿ représente hydrogène, halogène, alkyle C¿1-6?, alcoxy C¿1-6?, ou trifluorométhyle, R?2¿ représente alkyle C¿1-18?, aryle C¿6-10?, arylalkyle C¿7-15?, Het-alkyle où la fraction alkyle possède 1 à 6 atomes de carbone, Het représente un groupe (a) ou (b); R?2a¿ représente alkylène C¿1-3?, G représente oxygène, soufre ou azote, R?3¿ et R?4¿ représentent chacun indépendamment hydrogène, halogène, alkyle C¿1-3?, aryle C¿6-10?, ou un noyau hétérocyclique possédant 5 à 7 chaînons contenant 1 à 3 hétéroatomes choisis parmi oxygène azote, soufre; R?5¿ représente hydrogène, alkyle C¿1-6?, -CH(R?7¿)R?8¿, -C(CH¿2?)¿n?CO¿2?R?9¿, -C(CH¿3?)¿2?CO¿2?R?9¿, -CH(R?7¿)(CH¿2?)¿n?CO¿2?R?9¿, ou CH(R?7¿)C¿6?H¿4?CO¿2?R?9¿; R?6¿ représente hydrogène, halogène, alkyle C¿1-6?, ou OR?5¿; m vaut 1 à 6, n vaut 1 à 6 ; R?7¿ représente hydrogène, alkyle C¿1-6?, aryle C¿6-10?, ou arylalkyle C¿7-15?; R?8¿ représente CO¿2?R?10¿, -CONHR?10¿, tétrazole ou PO¿3?; R?9¿ et R?10¿ représentent chacun indépendamment hydrogène, alkyle C¿1-6?, aryle C¿6-10?, ou arylalkyle C¿7-15?. L'invention concerne également un sel de ces composés, acceptable sur le plan pharmacologique. Ces composés et ce sel sont utiles dans le traitement des troubles métaboliques associés à l'insulinorésistance ou à l'hyperglycémie.
CA002331120A 1998-05-12 1999-05-10 Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie Abandoned CA2331120A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7659698A 1998-05-12 1998-05-12
US09/076,596 1998-05-12
PCT/US1999/010211 WO1999058519A1 (fr) 1998-05-12 1999-05-10 Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie

Publications (1)

Publication Number Publication Date
CA2331120A1 true CA2331120A1 (fr) 1999-11-18

Family

ID=22133037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002331120A Abandoned CA2331120A1 (fr) 1998-05-12 1999-05-10 Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie

Country Status (6)

Country Link
EP (1) EP1077965A1 (fr)
JP (1) JP2002514636A (fr)
CN (1) CN1308621A (fr)
AU (1) AU3791799A (fr)
CA (1) CA2331120A1 (fr)
WO (1) WO1999058519A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
EP1366012A4 (fr) 2001-02-09 2005-11-02 Merck & Co Inc Acides 2-aryloxy-2-arylalcano ques utilis s pour le traitement du diab tes et des troubles lipidiques
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050065208A1 (en) * 2001-07-20 2005-03-24 Bodo Brandts Benzofuranes and their use in the treatment of atrial fibrillation
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569901B1 (fr) 2002-12-10 2008-10-15 Wyeth Derives d'acide 1h-indol-3-yl glyoxylique a substitution aryle, aryloxy et alkyloxy en tant qu'inhibiteurs de l'inhibiteur de l'activateur du plasminogene-1 (pai-1)
DE60327550D1 (de) 2002-12-10 2009-06-18 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60306547T2 (de) 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
FR2862646B1 (fr) * 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
FR2864536B1 (fr) * 2003-12-24 2006-03-17 Clariant France Sa Procede de preparation de n-alkyl-2 (hydroxy-4-benzoyl)-3 benzofurannes et intermediaires pour sa mise en oeuvre
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
JP5844376B2 (ja) * 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
CN102718735B (zh) * 2012-05-28 2014-04-23 沈阳药科大学 2-乙基-3-（4-羟基）苯甲酰基苯并呋喃类化合物、组合物及其制备方法
ME03061B (fr) 2013-02-19 2019-01-20 Novartis Ag Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des strogènes
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2023149549A1 (fr) * 2022-02-03 2023-08-10 国立大学法人富山大学 Nouvelle composition pharmaceutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012042A (en) * 1956-12-21 1961-12-05 Belge Produits Chimiques Sa Benzofurans
DE3342624A1 (de) * 1983-11-25 1984-03-29 Heinfried Dr. 4019 Monheim Grote Benzaronderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
FR2653431B1 (fr) * 1989-10-23 1994-05-27 Sanofi Sa Procede de preparation de derives de benzoyl-3 benzofuranne.
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
SE9101509D0 (sv) * 1991-05-17 1991-05-17 Karobio Ab Receptor ligands
DE4239429A1 (de) * 1992-11-24 1994-05-26 Merck Patent Gmbh Verfahren zur Herstellung von Immunkonjugaten
GB9416219D0 (en) * 1994-08-11 1994-10-05 Karobio Ab Receptor ligands
WO1997040017A2 (fr) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulateurs de molecules possedant des unites de reconnaissance de la phosphotyrosine
DE19624292A1 (de) * 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron

Also Published As

Publication number Publication date
JP2002514636A (ja) 2002-05-21
WO1999058519A1 (fr) 1999-11-18
AU3791799A (en) 1999-11-29
CN1308621A (zh) 2001-08-15
EP1077965A1 (fr) 2001-02-28

Similar Documents

Publication Publication Date Title
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
CA2331120A1 (fr) Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6110963A (en) Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
AU756337B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
US6369072B2 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077967B1 (fr) Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6251936B1 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
CA2330623A1 (fr) 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie
US6699896B1 (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
CA2331118A1 (fr) Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
EP1077966B1 (fr) Acides biphenyl-sulfonyl-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6310081B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
MXPA00011083A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011090A (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011085A (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
CZ20004182A3 (cs) Deriváty benzothiofenu, benzofuranu a indolu
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia

Legal Events

Date Code Title Description
FZDE Dead